Secukinumab in subjects with moderate-to-severe plaque psoriasis: Results from the Efficacy of Response And Safety of 2 fixed secUkinumab REgimens in psoriasis (ERASURE)

被引：0
|
作者：
Elewski, B.
Lebwohl, M.
Papp, K.
Nakagawa, H.
Sigurgeirsson, B.
Tsai, T.
Tyring, S.
Hampele, I.
Karpov, A.
Helou, S.
Papavassilis, C.
机构：
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2014年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：15 / 15
页数：1
相关论文
共 50 条
  • [31] Combination therapy of apremilast and secukinumab in patients with moderate-to-severe, recalcitrant plaque psoriasis
    Sacchelli, L.
    Patrizi, A.
    Loi, C.
    Bardazzi, F.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2019, 44 (07) : E243 - E244
  • [32] Reply to: "Comment on 'Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis"'
    Egeberg, Alexander
    Bryld, Lars Erik
    Skov, Lone
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (06) : E379 - E379
  • [33] Secukinumab in subjects with moderate-to-severe plaque psoriasis: Long-term safety and efficacy from an extension of a randomized, phase 2, regimen-finding study
    Philipp, S.
    Ortonne, J. P.
    Thaci, D.
    Sigurgeirsson, B.
    Kircik, L.
    Schopf, R.
    Harfst, E.
    Thurston, H. J.
    Papavassilis, C.
    Cooper, S.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2014, 12 : 14 - 14
  • [34] DOSE OPTIMIZATION OF SECUKINUMAB IN SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: OPTIMISE STUDY
    Reich, Kristian
    Puig, Lluis
    Szepietowski, Jacek
    Paul, Carle
    Rissler, Michael
    Sieder, Christian
    Orsenigo, Roberto
    Chaouche-Teyara, Kamel
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 11 - 12
  • [35] Multiple imputation methodology is reflective of secukinumab efficacy in real clinical practice: data from the FIXTURE and ERASURE studies in moderate-to-severe plaque psoriasis
    Langley, R. G.
    Reich, K.
    Papavassilis, C.
    Fox, T.
    Gong, Y.
    Guettner, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 (06) : E165 - E165
  • [36] Real world data with secukinumab for moderate-to-severe plaque psoriasis: Evaluation of safety, efficacy and drug survival in 50 patients
    Gkini, Maria-Angeliki
    Bewley, Anthony
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB114 - AB114
  • [37] Secukinumab safety in subjects with moderate to severe plaque psoriasis: A pooled analysis of neutropenia from 10 clinical studies
    Griffiths, Cristopher
    Guettner, Achim
    Prinz, Jorg
    Cooper, Simon
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB188 - AB188
  • [38] Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study
    Mrowietz, Ulrich
    Bachelez, Herve
    Burden, A. David
    Rissler, Michael
    Sieder, Christian
    Orsenigo, Roberto
    Chaouche-Teyara, Kamel
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 80 (05) : 1344 - 1352
  • [39] Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study
    Blauvelt, Andrew
    Reich, Kristian
    Tsai, Tsen-Fang
    Tyring, Stephen
    Vanaclocha, Francisco
    Kingo, Kulli
    Ziv, Michael
    Pinter, Andreas
    Vender, Ronald
    Hugot, Sophie
    You, Ruquan
    Milutinovic, Marina
    Thaci, Diamant
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (01) : 60 - +
  • [40] Secukinumab treatment demonstrated high efficacy and safety in pediatric patients with moderate-to-severe plaque psoriasis: 52-week results from a randomized trial
    Magnolo, Nina
    Kingo, Kulli
    Laquer, Vivian
    Browning, John
    Reich, Adam
    Szepietowski, Jacek C.
    Keefe, Deborah
    Mazur, Rafal
    Ghelani, Prayashi
    Forrer, Pascal
    Patekar, Manmath
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB119 - AB119
12345